MRK Merck & Co.
FY2024 10-K
Merck & Co. (MRK) filed its fiscal year 2024 10-K annual report with the SEC on Feb 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business model: Global pharmaceutical company focused on innovative drug discovery, development, manufacturing, and commercialization
- • New emphasis on immuno-oncology and ophthalmology: Acquisitions/license agreements for MK-2010 (bispecific PD-1/VEGF antibody), MK-4082 (oral GLP-1 receptor agonist), MK-1045 (bispecific antibody for B-cell diseases), EyeBio ($1.2B acquisition, MK-3000 tri-specific antibody), Harpoon ($765M immunotherapy acquisition)
Management Discussion & Analysis
- • Revenue $64.2B in 2024, up 7% YoY ($60.1B in 2023), or 10% excluding foreign exchange impact
- • Operating segments: Pharmaceutical (not quantified separately) and Animal Health (contributed to growth)
Risk Factors
- • U.S. and international patent disputes threaten market exclusivity for key products impacting revenue protections
- • Significant sales decline expected for Gardasil/Gardasil 9 vaccine in China in 2025 following lower 2024 sales
Financial SummaryXBRL
Revenue
$64.2B
Net Income
$17.1B
Net Margin
26.7%
ROE
37.0%
Total Assets
$117.1B
EPS (Diluted)
$6.74
Operating Cash Flow
$21.5B
Source: XBRL data from Merck & Co. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Merck & Co. Annual Reports
Get deeper insights on Merck & Co.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.